| アブストラクト | AIMS: The aim of this study was to investigate the association between weight change and healthcare resource use (HCRU) and costs in English primary care patients with type 2 diabetes mellitus (T2DM) initiating treatment with a new diabetes medication class. METHODS: Patients diagnosed with T2DM initiating a new diabetes medication class (first-line, switch or add-on treatment) were selected from Clinical Practice Research Datalink. Weight change (index date) was measured 6 months after initiating new treatment. HCRU was derived up to 1 year after index. Adjusted analyses evaluated the association between weight change and HCRU and costs (GBP, 2013 prices). RESULTS: Of 9031 patients, about half (n = 4901) experienced < 3% weight change (weight neutral); the proportions gaining or losing weight were similar. Compared with the weight neutral group, weight gain was associated with significantly increased total costs within a year (3.0-5.4% weight gain: pound58.9; p = 0.01, >/= 5.5% weight gain: pound52.9; p = 0.04) and diabetes primary care costs (3.0-5.4% weight gain: pound29.2; p < 0.001, >/= 5.5% weight gain: pound34.2; p < 0.001). This included increased rates of prescribing drugs for diabetes and, in >/= 5.5% weight gain, increased primary care contacts. A >/= 5.5% weight loss was associated with increased hospital admissions (odds ratio = 1.4; p < 0.0001) and total costs ( pound126.3; p < 0.001). CONCLUSION: Weight gain after initiating a new glucose-lowering medication is associated with increased prescribing and contact with primary care clinicians, with increased costs in primary care and total spending. This study supports that weight gain in diabetes is associated with increased healthcare costs. |
|---|
| ジャーナル名 | International journal of clinical practice |
|---|
| Pubmed追加日 | 2015/12/2 |
|---|
| 投稿者 | Blak, B T; Rigney, U; Sternhufvud, C; Davis, J; Hammar, N |
|---|
| 組織名 | Payer Evidence, AstraZeneca, Luton, UK.;Global Medicines Development, AstraZeneca, Molndal, Sweden.;MASD, US Payer & Real World Evidence, AstraZeneca, Wilmington, DE, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/26620492/ |
|---|
